News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA
Defence Therapeutics Inc. receives Health Canada's No Objection Letter for Phase I trial of ACCUM-002 as anti-cancer drug in melanoma patients. The study aims to assess safety, tolerability, and efficacy of the drug -
COMMUNIQUÉ DE PRESSE
COFICERT: COFICERT and Renoir Consulting sign a strategic partnership for the deployment of the certification standard: ESG 1000
COFICERT and Renoir Consulting announce strategic partnership for the deployment of ESG 1000 certification standard, enhancing Sustainability & CSR practices globally